title: [In search of optimal treatment for nonischemic ventricular arrhythmia in patients with anxiety disorders].
abstract: OBJECTIVE
  To assess whether arrhythmias may be corrected with the anxiolytic Adaptol in subjects with anxiety disorders.
  
  
  METHODS
  On the basis of the data of psychological and mental testing (Stroop test) and the results of Holter monitoring, the authors selected among 59 patients with non-coronarogenic ventricular arrhythmias (VA) and an inadequate response to antiarrhythmic therapy 21 patients with manifest anxiety disorders, in whom a psychogenic factor had played a significant role in the genesis of VA, which served as an indication for Adaptol use. Reexaminations were made 30 days after initiation of therapy with Adaptol 500 mg t.i.d.
  
  
  RESULTS
  Adaptol used to treat VA in patients with high anxiety, unlike the controls, exerted a significant antiarrhythmic effect: the average daily and average hourly number of ventricular ectopic complexes significantly decreased while there were no changes in the control group (untreated with Adaptol). In 95% of the patients, the positive Stroop mental test became negative, i.e. it failed to provoke arrhythmia (p < or = 0.01), made test performance easy, and diminished a blood pressure response to the test. The number of patients with moderate and high situational anxiety decreased by 3 times (p < or = 0.01); the general condition improved in the majority of patients.
  
  
  CONCLUSIONS
  The psychogenic factor plays a significant and sometimes determining role in the genesis of non-coronarogenic VA. When used alone and in combination with antiarrthythmics, Adaptol proved to be effective in treating non-coronarogenic VA in patients with higher anxiety.
authors.forename: T V
authors.initials: TV
authors.lastname: Treshkur
authors.forename: E A
authors.initials: EA
authors.lastname: Tsurinova
authors.forename: T É
authors.initials: TÉ
authors.lastname: Tulintseva
authors.forename: E V
authors.initials: EV
authors.lastname: Parmon
authors.forename: D Iu
authors.initials: DIu
authors.lastname: Il'ina
mesh_terms: D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000009:adverse effects; D000889:Anti-Arrhythmia Agents; D001007:Anxiety / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D001736:Biureas / Q000008:administration & dosage / Q000009:adverse effects; D016903:Drug Monitoring / Q000379:methods; D015716:Electrocardiography, Ambulatory; D005080:Exercise Test; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011581:Psychological Tests; D016896:Treatment Outcome; D018879:Ventricular Premature Complexes / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000523:psychology
chemical_list: D014151:Anti-Anxiety Agents; D000889:Anti-Arrhythmia Agents; D001736:Biureas; C015979:mebikar